Look no further than our top two stories of the year, and you’ll see that the GLP-1 craze and Big Pharma layoffs took center ...

Pfizer's efficiency at spending on R&D and Capex is set to look much better. Click here to see why PFE stock is a Buy.

We recently published a list of the 10 Best Stocks to Buy and Hold For 3 Years. In this article, we are going to take a look ...

Stock market investors have plenty of reasons to celebrate as 2024 comes to a close. Questions regarding the path of ...

Pfizer's trailing-12-month (TTM) revenue is $59.3 billion, whereas its TTM normalized diluted earnings per share (EPS) is ...

What we can glean from the pattern of accidental discoveries in science, especially in the pharmaceutical industry, and their ...

We recently published a list of the 8 Best Dividend Leaders to Buy According to Wall Street Analysts. In this article, we are ...

The U.S. Food and Drug Administration has approved Novo Nordisk's drug for the prevention or reduction of bleeding episodes ...

Louis Llovio is the deputy managing editor at the Business Observer. Before going to work at the Observer, the longtime ...

Pfizer said Friday that the Food and Drug Administration approved its treatment for patients with metastatic colorectal cancer.

Pfizer (PFE) has received FDA accelerated approval for its drug Braftovi in combination with other therapies for the ...

Big moments filled pharma marketing’s 2024. Pfizer made the leap into the Super Bowl, a number of campaigns won big in Cannes ...